Literature DB >> 2767014

The neuropathology of vigabatrin.

W H Butler1.   

Abstract

Vigabatrin (gamma vinyl GABA, GVG), an enzyme-activated, irreversible inhibitor of GABA transaminase, was administered orally to rats, dogs, and monkeys to observe toxicologic reactions. Myelin vacuolation of the brain was observed. The vacuolation was limited to myelinated tracts and resulted from separation of the myelin sheath at the interperiod line. There was no evidence of demyelination, axonal degeneration, or damage uolation was histologically similar to that observed in association with other drugs such as triethyltin, isoniazid, or hexachlorophene. However, the distribution is limited to the brain and is reversible upon discontinuation of therapy. Two postmortem and three operative specimens from humans have revealed no evidence of vacuolation of myelin.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2767014     DOI: 10.1111/j.1528-1157.1989.tb05827.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  10 in total

Review 1.  Ocular adverse effects associated with systemic medications : recognition and management.

Authors:  Ricardo M Santaella; Frederick W Fraunfelder
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Evaluating risks for vigabatrin treatment.

Authors:  Gregory L Krauss
Journal:  Epilepsy Curr       Date:  2009 Sep-Oct       Impact factor: 7.500

3.  Vigabatrin associated retinal dysfunction in children with epilepsy.

Authors:  R Koul; A Chacko; A Ganesh; S Bulusu; K Al Riyami
Journal:  Arch Dis Child       Date:  2001-12       Impact factor: 3.791

4.  Selective death of immature neurons in methylmalonic acidemia of the neonate: a case report.

Authors:  J M Sum; J L Twiss; D S Horoupian
Journal:  Acta Neuropathol       Date:  1993       Impact factor: 17.088

Review 5.  Vigabatrin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control.

Authors:  S M Grant; R C Heel
Journal:  Drugs       Date:  1991-06       Impact factor: 9.546

6.  Experimental neurotoxicity of 5-fluorouracil and its derivatives is due to poisoning by the monofluorinated organic metabolites, monofluoroacetic acid and alpha-fluoro-beta-alanine.

Authors:  R Okeda; M Shibutani; T Matsuo; T Kuroiwa; R Shimokawa; T Tajima
Journal:  Acta Neuropathol       Date:  1990       Impact factor: 17.088

Review 7.  Adverse reactions to new anticonvulsant drugs.

Authors:  I C Wong; S D Lhatoo
Journal:  Drug Saf       Date:  2000-07       Impact factor: 5.606

8.  Effect of vigabatrin on sedation and cognitive function in patients with refractory epilepsy.

Authors:  R A Gillham; J Blacklaw; P J McKee; M J Brodie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1993-12       Impact factor: 10.154

Review 9.  Visual field defects with vigabatrin: epidemiology and therapeutic implications.

Authors:  R Kälviäinen; I Nousiainen
Journal:  CNS Drugs       Date:  2001       Impact factor: 6.497

10.  Treatment of refractory complex partial seizures: role of vigabatrin.

Authors:  Elizabeth J Waterhouse; Kimberly N Mims; Soundarya N Gowda
Journal:  Neuropsychiatr Dis Treat       Date:  2009-10-12       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.